CANCER AND LEUKEMIA GROUP B - MOUNT SINAI

B 组癌症和白血病 - 西奈山

• 批准号: 3555813
• 负责人: JAMES F HOLLAND
• 金额: $ 18.67万
• 依托单位: MOUNT SINAI SCHOOL OF MEDICINE OF CUNY
• 依托单位国家: 美国
• 财政年份: 1979
• 资助国家: 美国
• 起止时间: 1979-04-01 至 1988-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3555813
• 关键词: 6 thiopurine; Hodgkin's disease; Mycobacterium bovis; adult human (21+); asparaginase; breast neoplasms; carmustine; chlorambucil; chloroquine; combination cancer therapy; cooperative study; cyclophosphamide; cytosine arabinoside; daunorubicin; doxorubicin; drug adverse effect; histiocytic lymphoma; human subject; human therapy evaluation; immunoglobulins; immunologic skin test; lomustine; lymphocytic leukemia; lymphoma; lymphosarcoma; methotrexate; multiple myeloma; myelogenous leukemia; myeloma globulin; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer immunodiagnosis; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; nephroblastoma; pediatric neoplasm /cancer; prednisone; procarbazine; splenectomy; vincristine

a. To participate in the cooperative studies of the various therepeutic regimens in acute leukemia, chronic leukemia, the lymphomas, breast cancer, lung cancer and other cancers in adults to be studied by the Cancer and Leukemia Group B. b. The toxicity and therapeutic range of new agents will be determined in Phase I studies; the frequency, extent and duration of remission with new agents will be evaluated in the Phase II studies; and the relative efficacy of various therapeutic regimens at different stages of the disease will be determined in Phase III studies. c. To participate in the surgical, radiotherapeutic, immunologic and cytogenetic, psychiatric, pathological, chemotherapeutic and nursing oncology aspects of CALGB investigations. d. To utilize the case material for the cooperative chemotherapy studies for ancillary investigations of some of the biological, biochemical and immunological aspects of the neoplastic diseases under study. e. Laboratory animals will not be used.

一个。参与各种此处的合作研究 急性白血病，慢性白血病，淋巴瘤，乳腺癌的方案 肺癌和成年人中的其他癌症，由癌症和 白血病组。 b。新药物的毒性和治疗范围将在 第一阶段的研究；新的频率，程度和持续时间 将在II期研究中评估药物；和相对功效 在疾病的不同阶段，各种治疗方案将是 在第三阶段研究中确定。 c。参加手术，放射治疗，免疫学和 细胞遗传学，精神病学，病理，化学治疗和护理 CALB调查的肿瘤学方面。 d。利用案例材料进行合作化疗研究 为了对一些生物学，生化和 正在研究的肿瘤疾病的免疫学方面。 e。将不会使用实验动物。